|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002085,
umls-concept:C0042210,
umls-concept:C0328767,
umls-concept:C0332197,
umls-concept:C0871261,
umls-concept:C1097566,
umls-concept:C1422055,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1709854,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-7-21
|
|
pubmed:abstractText |
According to a number of previous reports, control of HIV replication in humans appears to be linked to the presence of anti-HIV-1 Gag-specific CD8 responses. During the chronic phase of HIV-1 infection, up to 75% of the HIV-infected individuals who express the histocompatibility leukocyte Ag (HLA)-A*0201 recognize the Gag p17 SLYNTVATL (aa residues 77-85) epitope (SL9). However, the role of the anti-SL9 CD8 CTL in controlling HIV-1 infection remains controversial. In this study we determined whether the pattern of SL9 immunodominance in uninfected, HLA-A*0201 HIV vaccine recipients is similar to that seen in chronically HIV-infected subjects. The presence of anti-SL9 responses was determined using a panel of highly sensitive cellular immunoassays, including peptide:MHC tetramer binding, IFN-gamma ELISPOT, and cytokine flow cytometry. Thirteen HLA-A*0201 vaccinees with documented anti-Gag CD8 CTL reactivities were tested, and none had a detectable anti-SL9 response. These findings strongly suggest that the pattern of SL9 epitope immunodominance previously reported among chronically infected, HLA-A*0201-positive patients is not recapitulated in noninfected recipients of Gag-containing canarypox-based candidate vaccines and may be influenced by the relative immunogenicity of these constructs.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AIDS Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, gag,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A*02:01 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Immunodominant Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, DNA,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/env Gene Products, Human...,
http://linkedlifedata.com/resource/pubmed/chemical/p17 gag peptide, human...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
pubmed-author:BettsMichael RMR,
pubmed-author:BuchbinderSusanS,
pubmed-author:EdwardsBradley HBH,
pubmed-author:FerrariGuidoG,
pubmed-author:GoepfertPaulP,
pubmed-author:JonesAnizsa MAM,
pubmed-author:KoupRichard ARA,
pubmed-author:McElrathM JulianaMJ,
pubmed-author:NealWesleyW,
pubmed-author:OttingerJanetJ,
pubmed-author:TartagliaJimJ,
pubmed-author:WeinholdKent JKJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
173
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2126-33
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15265949-AIDS Vaccines,
pubmed-meshheading:15265949-Alleles,
pubmed-meshheading:15265949-Canarypox virus,
pubmed-meshheading:15265949-Epitopes, T-Lymphocyte,
pubmed-meshheading:15265949-Gene Products, gag,
pubmed-meshheading:15265949-HIV Antigens,
pubmed-meshheading:15265949-HIV Infections,
pubmed-meshheading:15265949-HIV Seronegativity,
pubmed-meshheading:15265949-HIV-1,
pubmed-meshheading:15265949-HLA-A Antigens,
pubmed-meshheading:15265949-HLA-A2 Antigen,
pubmed-meshheading:15265949-Humans,
pubmed-meshheading:15265949-Immunization, Secondary,
pubmed-meshheading:15265949-Immunodominant Epitopes,
pubmed-meshheading:15265949-Peptide Fragments,
pubmed-meshheading:15265949-T-Cell Antigen Receptor Specificity,
pubmed-meshheading:15265949-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:15265949-Vaccination,
pubmed-meshheading:15265949-Vaccines, DNA,
pubmed-meshheading:15265949-Vaccines, Synthetic,
pubmed-meshheading:15265949-env Gene Products, Human Immunodeficiency Virus
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
|
|
pubmed:affiliation |
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. gflmp@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
